Inclusion Criteria:  HC Participants:  Is in generally good health Has no history of clinically relevant neuropsychiatric illness Is a mild-to-moderate tobacco user of ≥1-year duration, smoking the equivalent of ~10-15 cigarettes/day  Participants with SZ of Mild-to-Moderate Severity:  Has a current diagnosis of SZ with a duration ≥1 year Is clinically stable and in the residual (non-acute) phase of illness for ≥12 weeks prior to the study Is stably maintained on a regimen of up to 2 first- or second-generation antipsychotics with no dose changes >50% in combination with concomitant medication commonly prescribed to this population for ≥8 weeks prior to screening and during the study Is a mild-to-moderate tobacco user of ≥1-year duration, smoking the equivalent of ~10-15 cigarettes/day  All Participants:  For males, agrees to be abstinent from heterosexual intercourse, or use an approved contraception method, during the study and for 90 days after the last dose of study drug For females, is not of childbearing potential Is willing to comply with restrictions on the use of nicotine or nicotine-containing products during the study  Exclusion Criteria:  HC Participants:  Has known biological family history of psychotic disorder in a first or second degree relative  Participants with SZ of Mild-to-Moderate Severity:  May be excluded from participation by the investigator based on treatment history and/or performance on various screening tests  All Participants:  Is positive for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV) Is at imminent risk of self-harm Has had major surgery or donated blood within 4 weeks prior to screening Has evidence of cognitive impairment or significant mental disability Has a history of clinically significant abnormality or disease Has a history of cancer (malignancy) Is unable to refrain, or anticipates use, of any non-prescription drugs or herbal remedies Has participated in another clinical study within 6 weeks or 5 half-lives (whichever is greater) prior to screening